Why Amgen’s recent move is tied to earnings and pipeline news Amgen (AMGN) has been back on many investors’ screens after a strong third quarter, with double digit revenue growth and a wider mix of ...

If you want to know who really controls Amgen Inc. (NASDAQ:AMGN), then you'll have to look at the makeup of its share ...

Investing.com -- Bernstein cut its rating on Amgen Inc (NASDAQ:AMGN) to Market-Perform from Outperform, keeping its $335 price target, saying 2026 is likely to be a waiting year with limited catalysts ...

Johnson & Johnson reports Q4 earnings Jan 21 with 22% EPS growth expected. Stelara biosimilars and talc verdict weigh on ...

Amgen says its MariTide obesity drug helped patients maintain weight loss for a second year, with good safety and fewer side ...

Compass Therapeutics, Inc. is rated a Buy with strong cash position and strong data readout by the end of 1H 2026. Read more ...

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Halozyme ...

FOLD, MU and AMGN delivered sharp gains as Zacks strategies beat key benchmarks despite tariff fears, policy uncertainty and ...

Amgen (AMGN) closed at $328.97 in the latest trading session, marking a +1.44% move from the prior day. This move outpaced ...

In a report released today, Louise Chen from Scotiabank maintained a Buy rating on Amgen, with a price target of $385.00. According to TipRanks, Chen is a 3-star analyst with an average return of 1.3% ...

India's largest drugmaker, Sun Pharma, is considering a major acquisition. The company is evaluating the purchase of US-based ...

Sun Pharma has engaged a European bank as an advisor to structure a comprehensive financial proposal that may be presented to ...